Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its anesthetic propofol encouraged re-use and led to colonoscopy patients developing hepatitis C. The company no longer makes the drug. The money will settle about 120 lawsuits, mostly from patients of a Nevada colonoscopy center. It will also settle a case in which it faced a $500 million jury award. Story